US pulls GSK’s COVID drug as omicron sibling dominates cases | Health/Fitness
WASHINGTON (AP) — GlaxoSmithKline’s IV drug for COVID-19 ought to not be used as a result of it's probably ineffective in opposition to the omicron subvariant that now accounts for many U.S. circumstances, federal well being regulators stated Tuesday.The Meals and Drug Administration introduced that the corporate’s antibody drug sotrovimab is not licensed to deal with sufferers in any U.S. state or territory. The ...